Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.791
Abstract: We report pharmacokinetics, pharmacodynamics, and safety of a novel anti‐CD28 domain antibody antagonist (lulizumab pegol) in healthy subjects following single‐ or multiple‐dose administration. A minimal anticipated biological effect level approach was used to select a… read more here.
Keywords: antibody antagonist; anti cd28; novel anti; domain antibody ... See more keywords
Mutation of the TGN1412 anti-CD28 Monoclonal Antibody Lower Hinge Confers Specific FcγRIIb Binding and Retention of Super-Agonist Activity.
Sign Up to like & getrecommendations! Published in 2023 at "Immunology and cell biology"
DOI: 10.1111/imcb.12646
Abstract: The agonistic action of several immunomodulatory monoclonal antibodies (mAb) requires both target antigen binding and clustering of this mAb:target complex by the Fcs interacting with Fcγ receptors (FcγR), in particular FcγRIIb, on neighbouring bystander cells.… read more here.
Keywords: igg4; tgn1412 anti; anti cd28; mutation ... See more keywords